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ABSTRACT 
 
BACKGROUND. Cardiovascular disease represents an important cause of morbidity and 
mortality in patients with a diagnosis of systemic lupus erythematosus (SLE), due to a 
complex interplay between traditional risk factors and disregulation of autoimmunity, but 
uncertainty is still present about the most important predictors of cardiovascular events. 
OBJECTIVES. Aim of our work is therefore to perform a collaborative systematic review 
on main predictors of cardiovascular events in SLE patients. 
METHODS.  PubMed, Cochrane was systematically searched for eligible studies on SLE 
and cardiovascular events between January 2008 and December 2012. Study features, 
patient characteristics, and incidence of stent thrombosis were abstracted and pooled, 
when appropriate, with random-effect methods (point estimate [95% confidence 
intervals]),and consistency of predictors was formally appraised. 
RESULTS. A total of 17187 patients were included; of those, 93.1% were female, and the 
median age was of 39 years. After a median follow-up period of 8 years, cardiovascular 
events presented in 25.4%, including acute myocardial infarction (4.1%) and stroke 
(7.3%). The most important predictors may be divided in traditional risk factors, like male 
gender (OR 6.2, CI 95% 1.49 - 25), hyperlipaemia (OR 3.9, CI 95% 1.57 – 9.71), familiar 
history of cardiac disease (OR 3.6, CI 95% 1.15 – 11.32) and hypertension (OR 3.5, CI 
95% 1.65 – 7.54),and SLE-related features, like the presence of auto-antibodies (OR 5.8 
and 5.0, CI 95% 3.28 – 7.78) and neurological disorders (OR 5.2, CI 95% 2.0 – 13.9). A 
low correlation was shown for importance of organ damage and SLE activity (respectively 
OR 1.4, CI 95% 1.09 – 4.44 and OR 1.2, CI 95% 1.2 – 1.2), as well as for the age at 
diagnosis (OR 1.1, CI 95% 1.07 – 1.17). 
CONCLUSIONS. Cardiovascular events in SLE patients are caused by a multifactorial 
mechanism, including both traditional and disease-specific risk factors. A global valuation 
with an individual risk-stratification based on both  these features is important to correctly 
manage these patients in order to reduce negative outcomes. 
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INTRODUCTION 
Systemic lupus erythematosus (SLE) represents a chronic autoimmune disorder 
displaying a wide spectrum of clinical manifestations, ranging from malar rash, arthralgias 
and characteristic plasma autoantibodies to life-threatening manifestations such as 
nephritis or thrombosis. In the past, renal and central nervous system involvement were 
the main causes of mortality. 1 2 3  but with the therapy improvement, especially steroid 
treatment, life expectancy extended, with a parallel increased cardiovascular mortality and 
morbidity. 
Traditional risk factors (like diabetes, hypertension, hyperlipidemia and smoking 
addiction) are common in these young patients, probably as a side effect of 
immunosuppressant therapy; 4 5 on the other side, from a pathological and clinical point of 
view, they do not completely explain the increased frequency and the early presentation of 
cardiovascular disease in this population. 6 7 8 Probably increased inflammatory response, 
as well as steroid therapy, may play a crucial role in atherogenesis. 9 10 11 12 Several 
studies have been made to investigate this topic and to identify some predictors of the 
thrombosis burden, a crucial step to prevent undesirable outcomes. 13 14 15 16  
However, the evidence of the increased cardiovascular disease incidence in the 
current era is fraught with conflicting data on risk and predictors, which remains difficult to 
overcome without a systematic approach. Therefore we aimed to perform a meta-analysis 
focusing on incidence and predictors of cardiovascular events in SLE patient. 
 
 
 
METHODS 
This work was conducted in keeping with current guidelines, including the recent 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
amendment to the Quality of Reporting of Meta-analyses (QUOROM) statement, as well 
as recommendations from The Cochrane Collaboration and Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE). 17 18 19 20 
 
2.1. Search strategy 
MEDLINE/PubMed was searched for pertinent articles published in English between 
January 2008 and December 2012 according to the following strategy, in keeping with 
established methods 21and incorporating wild cards (identified by *): (systemic lupus 
erythematosus OR SLE) AND (((coronary OR arterial) AND (stent* OR ptca OR 
angioplasty OR cabg OR bypass AND (graft* OR surgery))) OR (myocardial infarction OR 
dissection OR thrombosis OR acute coronary syndrome)). We choose the time criteria 
because of the publication in 2008 of the guidelines of the Eular that deeply impacted on 
clinical practice.22 
 
2.2. Study selection 
Retrieved citations were first screened independently by two unblinded reviewers at 
the title and/or abstract level, with divergences resolved after consensus. 
If potentially pertinent, they were then appraised as complete reports according to 
the following explicit selection criteria, which were piloted over the first 5 cases. Inclusion 
criteria were (all had to be met for inclusion): (i) human studies, (ii) investigating patients 
with diagnosis of systemic lupus erythematosus, defined by American College of 
Rheumatology criteria 23 24, with a thrombotic event, (iii) published between 2008 and 
2012, (iv) reporting predictors of cardiovascular events obtained through univariable or 
multivariable analysis. Exclusion criteria were (any one alone was enough for exclusion):(i) 
non-human setting, (ii) duplicate reporting (in which case the manuscript reporting the 
largest sample of patients with SLE and cardiovascular events was selected, or if equal, 
the study with the largest number of overall patients). 
 
2.3. Data extraction 
The following data were independently abstracted by two unblinded reviewers on 
pre-specified electronic forms, which were piloted over the first 5 cases, with divergences 
resolved after consensus. In particular, authors, journal, year of publication, baseline, 
disease and therapy features, events and multivariate predictors (estimator, point 
summary estimate of risk, 95% confidence intervals).  
End-points of interest for the present review were the incidence of cardiovascular 
events in SLE patients at the different time points as well as univariable and multivariable 
predictors of cardiovascular events. Given the exploratory yet comprehensive scope of this 
collaborative review, no explicit primary end-point was specified. 
 
2.4. Internal validity and quality appraisal 
The quality of included studies was independently appraised by two unblended 
reviewers on pre-specified electronic forms, which were piloted over the first 5 cases, with 
divergences resolved after consensus. Modifying the MOOSE item list in order to take into 
account the specific features of included studies, we separately abstracted and appraised 
study design, setting, data source, and statistical methods for univariable and multivariable 
analysis, as well as, in keeping with The Cochrane Collaboration approach, the risk of 
analytical, selection, adjudication, detection, and attrition bias (expressed as low, 
moderate, or high risk of bias, as well as incomplete reporting leading to inability to 
ascertain the underlying risk of bias). 
 
2.5. Data analysis and synthesis 
Continuous variables are reported as mean (standard deviation) or median (1st;3rd 
quartile). Categorical variables are expressed as n/N (%). Statistical pooling for incidence 
estimates was performed according to a random-effect model with genericinverse-variance 
weighting, computing risk estimates with 95% confidence intervals, using RevMan 5 (The 
Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). 
Conversely, risk estimates were not pooled from individual studies as this approach would 
have not been feasible and valid given the high risk for publication bias). We instead 
adopted Ross et al.'s approach 25, and appraised the prevalence of studies in which a 
given predictor was proven significantly and independently associated with the outcome of 
interest. Small study bias was appraised by graphical inspection of funnel plots. Using 
rates of event as dependent variable, a meta-regression was performed to test the effect 
of  clinical features. Hypothesis testing for superiority was set at the two-tailed 0.05 level. 
Hypothesis testing for statistical homogeneity was set at the two-tailed 0.10 level and 
based on the Cochran Q test, with I2 values of 25%,50%, and 75% representing, 
respectively, mild, moderate, and extensive statistical inconsistency. 
 
 
 
RESULTS 
3.1. Review profile and included studies 
From a total of 2799, 32 studies were included (Figure 1); the median follow-up was of 8 
years (1st quartile 6.7 years; 3rd quartile 8.8 years). 
A total of 17187 patients were included; of those, 93.1% were female, and the median age 
was of 39 years. Hypertension was reported in 42.6% of the patients, dyslipidemia in 44% 
and almost 20% were active smokers (Table 1). 
The median length of SLE diagnosis was 9 years, and most of the patients were in therapy 
with steroids (69.7%) and/or with other immunosuppressant (50.5%), and 36% with 
platelet inhibitors. Cardiovascular events presented in 25.4%, including acute myocardial 
infarction (4.1%) and stroke (7.3%) (Table 2). 
 
3.2. Frequency and consistency of SLE predictors in cardiovascular events 
Many candidate risk factors were considered in the included studies of our meta-analysis, 
some of them in common with the general population, some specific of SLE patients. The 
most frequently and consistently reported predictors of cardiovascular events in SLE 
patients were male gender (OR 6.2, CI 95% 1.49 - 25), presence of plasmatic anti-
cardiolipine antibodies (OR 5.8, CI 95% 2.22 – 15.5) and global anti-phospholipid 
antibodies (OR 5.0, CI 95% 3.28 – 7.78) and presence of neurological disorders (OR 5.2, 
CI 95% 2.0 – 13.9); dyslipidaemia (OR 3.9, CI 95% 1.57 – 9.71), familiar history of cardiac 
disease (OR 3.6, CI 95% 1.15 – 11.32), hypertension (OR 3.5, CI 95% 1.65 – 7.54), as 
well as azathioprine and steroid treatment also appeared significant predictors, even 
though less consistently. (Fig.2, Table 3) 
A low correlation was shown for importance of organ damage and SLE activity 
(respectively OR 1.4, CI 95% 1.09 – 4.44 and OR 1.2, CI 95% 1.2 – 1.2), as well as for the 
age at diagnosis (OR 1.1, CI 95% 1.07 – 1.17). However, it must be emphasized that 
these are not pooled estimates but estimates from singles studies, and thus at high risk of 
small study effects and reporting bias. These results were confirmed at a subsequent 
meta-regression analysis. 
 
3.3 Internal validity of the studies 
The most important features of this study are summarized in Table 4. The design was 
more frequently retrospective (56%), with a multicenter setting in 46.8%; most of the 
studies were conducted in North America (40.6%) and Europe (37.5%). 
 
 
 
 DISCUSSION 
Patients with systemic lupus erythematosus have an increased risk of 
cardiovascular events, especially a thrombotic event. To the best of our knowledge, this is 
the first systematic review focusing on incidence and predictors of cardiovascular events in 
SLE patients. In a total of 17187 patients from 32 studies, the incidence of cardiovascular 
events was almost 25%, and 4.5% of the patients had an acute myocardial infarction. 
None of the 17 candidate predictors identified occurred in all the studies included, 
reflecting the complex pathophysiology of cardiovascular events in SLE and the limitations 
in its classification, and the ensuing challenges in conducting case–control or cohort 
studies capable of providing precise, accurate, and consistent statistical results. 
Nevertheless, analyzing some candidate predictors of cardiovascular events in this 
population, it emerged that they may be divided in two groups: traditional risk factors and 
features of SLE patients. 
In the first group, male gender resulted to be one of the strongest predictor, but the 
weight of this feature should be carefully considered, remembering that the main part of 
SLE patients are women. An important role is also played by dyslipidemia, hypertension, 
familiar history of CAD (coronary artery disease) and smoking addiction. The prevalence of 
these risk factors in such young patients is unusual in the global population; the early 
onset of pathologies like hypertension and diabetes may be supposed to be related both to 
high inflammatory response due to the autoimmune disease, both to long-lasting 
pharmacological treatment with immunosuppressant, and especially steroids. The impact 
of cigarette smoking may be multifactorial: on one side, it may contribute to cardiovascular 
risk amplifying the classical atherogenic process. On the other hand, it may play a role on 
some aspects of SLE evolution: smoking has been associated with progression of lupus 
nephritis to end-stage renal disease, it may reduce the response to immunosuppressant 
therapies, and, causing a low-grade systemic inflammatory response, it may worsen the 
progression of the disease. 26 27 
In the second group, the highest correlation with cardiovascular events was shown 
by the presence of autoantibodies, like antiphospholipid antibodies, anticardiolipin and 
lupus anticoagulant, produced in thirty to forty percent of SLE patients. However, this risk 
factor doesn’t fully explain the increased thrombosis risk in SLE, because literature data 
show that only 10% of “positive” patients experience a thrombotic event, and 40% of SLE 
thrombosis cases are autoantibodies negative. 28 29 
A role in the increased risk of this population seemed to be associated with the 
therapy used to cure the autoimmune disease, both steroid and immune-suppressant. 30 
Part of the effect of these treatments may be related to their impact on hypertension, 
dyslipidaemia and diabetes, well known side-effects of steroids, explaining on the other 
side the high prevalence of these comorbidities in this young population. 31 Furthermore, 
high dosages of glucocorticoids are associated with a higher disease activity, and 
therefore they are probably a proxy for this variable. Nevertheless, the activity and severity 
of the disease, expressed by some multi-variable scores like Systemic SLE Damage and 
SLEDAI2K, as well as disease duration, seemed instead to have a smaller impact on 
cardiovascular risk. This result appears in contradiction with the hypothesis of the 
increased atherogenesis due to inflammatory response in SLE, underlaying the 
multifactorial mechanism of cardiovascular disease in these patients. 
Therefore, cardiovascular events in SLE patients cannot be systematically avoided 
just by addressing a single or a few risk factors, 
management of each individual patient. To correctly manage these patients, it becomes 
fundamental to individually risk-stratify the patient, stressing the importance of acting on 
modifiable common risk factors like hypertension and dyslipidemia, and accurately 
searching for SLE-specific features. 
 
Limits of this study 
Our systematic meta-analysis have some limitations related to the nature of the 
primary studies. First, more than half of the included studies were case-control or cross-
sectional studies rather than cohort studies, which did not have the same risk estimates. 
Second, we did not perform a pooled analysis of risk predictors, because this would have 
been limited by substantial reporting bias. 
Moreover, publication bias remains always a concern because the present review was 
based solely on published studies. Most predictors were appraised in only a subset of 
studies, limiting the precise quantitative estimation of their independent predictive role. 
 
 
CONCLUSIONS 
Systemic lupus erythematosus (SLE), an autoimmune disease with many 
presentations, is graved by an increased risk of cardiovascular events. Patients with this 
pathology, usually a young population, show a higher prevalence of common CAD risk 
factors, unusual for the early age, and a wide spectrum of autoimmune-disease specific 
features related to coronary artery events. 
A global evaluation with an individual risk-stratification based both on modifiable 
and SLE-specific risk factors of each patient is fundamental to correctly manage these 
patients in order to reduce negative outcomes. 
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